Investing.com - Merck&Co (NYSE: MRK) reported first quarter EPS of $2.07, $0.14 better than the analyst estimate of $1.93. Revenue for the quarter came in at $15.8B versus the consensus estimate of $15.22B.
Guidance
Merck&Co sees FY 2024 EPS of $8.53-$8.65 versus the analyst consensus of $8.56.
Merck&Co sees FY 2024 revenue of $63.10B-$64.30B versus the analyst consensus of $63.80B.
Merck&Co's stock price closed at $127.01. It is up 5.12% in the last 3 months and up 11.97% in the last 12 months.
Merck&Co saw 1 positive EPS revisions and 10 negative EPS revisions in the last 90 days. See Merck&Co's stock price’s past reactions to earnings here.
According to InvestingPro, Merck&Co's Financial Health score is "good performance".
Check out Merck&Co's recent earnings performance, and Merck&Co's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar